N-Terminal pro-brain natriuretic peptide in systemic sclerosis: New insights

European Journal of Dermatology

Volumn 21, Issue 5, 2011, Pages 686-690

  Elshamy, Hebatallah Ahmad ^a   Ibrahim, Soha Eldessouki ^a   Farouk, Hanan Mohamed ^a   Moustafa, Afaf A ^a   Aly, Iman Mohamed ^a   Osman, Wesam M ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

N terminal pro brain natriuretic peptide; Pulmonary affection; Skin fibrosis; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ARTERY PRESSURE; LUNG DISEASE; LUNG FUNCTION TEST; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANKIN SCALE; SKIN BIOPSY; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; SYSTOLIC PULMONARY ARTERY PRESSURE;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 80054891283     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1423     Document Type: Article

References (25)

1. Zhou X, Tan FK, Milewicz DM, Guo X, Bona CA, Arnett FC. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the "scleroderma phenotype. J Immunol 2005; 175: 4555-60.
2. Michele E, Carlo M, Claudio P, et al. Right ventricular overload and cardiovascular neuroendocrine derangement in systemic sclerosis. European Heart Journal Supplements 2004; 6 (Supplement F), F68-F73.
3. Dimitroulas T, Giannakoulas G, Karvounis H, Gatzoulis MA, Settas L. Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. Semin Arthritis Rheum 2010; 39: 278-84.
4. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 453-9.
5. Noritoshi N, Toshio N, Masaaki U, et al. Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients with Primary Pulmonary Hypertension. Circulation 2000; 102: 865.
6. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
7. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
8. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
9. Choi HJ, Shin YK, Lee HJ, et al. The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients. Clin Rheumatol 2008; 27: 437-442.
10. Verrecchia F, Laboureau J, Verola O, et al. Skin involvement in scleroderma-where histological and clinical scores meet. Rheumatology (Oxford) 2007; 46: 833-41.
11. Knapp RG, Miler MC. Clinical epidemiology and biostatistics. Harwal Publishing Company, 1992.
12. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-63.
13. Lambova S, Muller-Ladner U. Pulmonary arterial hypertension in systemic sclerosis. Autoimmun Rev 2010; 9: 761-70.
14. Oravec RM, Bredemeier M, Laurino CC, et al. NT-proBNP levels in systemic sclerosis: association with clinical and laboratory abnormalities. Clin Biochem 2010; 43: 745-9.
15. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59.
16. Carlo-Stella N, Belloli L, Biondi ML, Marasini B. Serum N-terminal pro-brain natriuretic peptide, a marker of skin thickness in systemic sclerosis? Clin Rheumatol 2009; 28: 241-2.
17. Giannoni A, Tani C, Clerico A, et al. When the heart is burning: Amino-terminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease. Int J Cardiol 2011; 148: 161-7.
18. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91: 1127-34.
19. Altin C, Aydinalp A, Kanyilmaz S, et al. N-Terminal Pro-Brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension. Int J Cardiol; 2010; 140: 537-8.
20. Allanore Y, Borderie D, Meune C, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calciumchannel blockers. Arthritis Rheum 2003; 48: 3503-8.
21. Allanore Y, Wahbi K, Borderie D, Weber S, Kahan A, Meune C. N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 2009; 68: 1885-9.
22. Han B, Hasin Y. Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1. Cardiovasc Drugs Ther 2003; 17: 41-52.
23. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-619.
24. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
25. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2006; 45 (Suppl. 4): iv14-17.